Myovant Sciences’ stock rocketed on news that the company was partnering with Pfizer to develop and commercialize Orgovyx (relugolix) for prostate cancer and women’s health.

ObsEva announced topline data from the PRIMROSE 1 and 2 Phase III trials of Yselty (linzagolix) for uterine fibroids.

Myovant announced topline results from SPIRIT 1, the second Phase III trial of once-daily relugolix combination therapy in women with pain linked with endometriosis.

Switzerland-based Myovant announced an 88 percent one-year response rate in the positive Phase III LIBERTY extension study of once-daily, oral relugolix combination therapy in women with heavy menstrual bleeding associated with uterine fibroids.

ObsEva SA reported positive Phase 3 trial results from the PRIMROSE 2 trial of linzagolix for the treatment of heavy menstrual bleeding (HMB) due to uterine fibroids.

Myovant announced that the company’s Phase III HERO trial relugolix met the study’s primary endpoint and six key secondary endpoints in advanced prostate cancer.